Telomir-1 Shows Promise in Restoring Vision in AMD Animal Model

Telomir Pharmaceuticals, Inc. reported significant preclinical results for its new drug, Telomir-1, in a zebrafish model of age-related macular degeneration (AMD). After a 14-day treatment, the drug reversed vision impairment and restored retinal structure. The study on aged zebrafish demonstrated a reversal of central vision loss and retinal degeneration, crucially reducing oxidative stress levels.

The zebrafish model used exhibited progressive retinal damage, resembling human dry AMD and geographic atrophy. Prior to treatment, they showed significant neurodegeneration and poor responses to stimuli. Post-treatment with Telomir-1, zebrafish exhibited better visual responses and reduced mortality.

Telomir-1 improved retinal architecture, restoring several critical retinal layers and reducing oxidative stress by 50%. According to CEO Erez Aminov, this marks a potential leap forward in treating AMD.